NCT06917079 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06917079
Title	BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Indications	lung non-small cell carcinoma Advanced Solid Tumor colorectal cancer pancreatic ductal adenocarcinoma
Therapies	BBO-11818 + Pembrolizumab BBO-11818 + Cisplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Carboplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Cetuximab BBO-11818
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 4 of 4 entries

Facility	Status	City	State	Zip	Country	Details
Huntsman Cancer Institute	RECRUITING	Salt Lake City	Utah	84112	United States	Details
NEXT Oncology	RECRUITING	San Antonio	Texas	78229	United States	Details
Sarah Cannon Research Institute at Mary Crowley	RECRUITING	Dallas	Texas	75230	United States	Details
The University of Texas MD Anderson Cancer Center	RECRUITING	Houston	Texas	77030	United States	Details

Showing 1 to 4 of 4 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06917079Clinical Trial Detail